Skip to main content

Table 1 Demographic and clinical characteristics of patients based on PainDETECT score

From: The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study

  PainDETECT ≤12 n = 25 PainDETECT 13-18 n = 9 PainDETECT ≥19 n = 16 Pvalue
Demographic and clinical     
Age, years 66 ± 9 63 ± 9 67 ± 7 0.392*
Female, n (%) 18 (72%) 5 (56%) 10 (63%) 0.629‡
Weight, kg 82.5 ± 14.1 81.0 ± 10.6 87.0 ± 18.9 0.587*
OA duration, years 7.7 ± 8.1 7.4 ± 6.6 8.1 ± 4.6 0.528*
BMI, kg/m2 31 ± 6 29.9 ± 3 33 ± 6 0.558*
NSAID users, n (%) 3 (12%) 0 (0%) 5 (31%) 0.114¶
PainDETECT 8.1 ± 2.6 15.6 ± 1.1 24.2 ± 4.2 <0.001♦
WOMAC     
 Pain (0–100) 43 ± 17 50 ± 13 65 ± 14 <0.001♦
 Function (0–100) 45 ± 23 52 ± 15 68 ± 14 <0.001♦
 Stiffness (0–100) 51 ± 24 49 ± 18 69 ± 16 0.007♦
 Total (0–100) 45 ± 21 51 ± 14 68 ± 13 <0.001♦
VAS pain (0–100 mm) 62 ± 14 62 ± 13 69 ± 13 0.023♦
Kellgren-Lawrence score     0.068†§
 2 14 (56%) 5 (56%) 5 (31%)  
 3 11 (44%) 4 (44%) 11 (69%)  
Inflammatory biomarkers     
Sedimentation rate, mm 12.4 ± 9.0 12.6 ± 5.5 15.2 ± 20.8 0.406♦
CRP, mg/l 4.3 ± 2.9 6.8 ± 9.1 5.0 ± 4.7 0.432♦
  1. Results are shown as mean ± standard deviation (SD) unless otherwise indicated. P values were assessed using the *Kruskal-Wallis test, the ‡chi-square test, the ¶Fisher’s exact test, the Jonckheere-Terpstra test for trend, or the †Cochran-Armitage trend test; §Includes both Kellgren-Lawrence scores. n, number of participants; OA, osteoarthritis; BMI, body mass index; NSAID, non-steroidal anti-inflammatory drug; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index (each subscale, 100 = worst score; total scale, 100 = worst score); VAS, visual analog scale (0 mm = no pain, 100 mm = most severe pain); CRP, C-reactive protein.